Year: 2024
Type: article
Abstract: INTRODUCTION: Understanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population-based or neuropathologic comparisons have been reported. METHODS: Participants 50+ years with Aβ PET and Aβ CSF biomarkers (phosphorylated tau [p-tau]181/Aβ42, n = 505, and Aβ42/40, n = 54) were included from the Mayo Clinic Study on Aging. From these participants, an autopsy subgroup was identified (n = 47). The relationships of Aβ PET and Aβ CSF biomarkers were assessed cross-sectionally in all participants and longitudinally in autopsy data. RESULTS: Cross-sectionally, more participants were Aβ PET+ versus Aβ CSF- than Aβ PET- versus Aβ CSF+ with an incremental effect when using Aβ PET regions selected for early Aβ deposition. The sensitivity for the first detection of Thal phase ≥ 1 in longitudinal data was higher for Aβ PET (89%) than p-tau181/Aβ42 (64%). DISCUSSION: Aβ PET can detect earlier cortical Aβ deposition than Aβ CSF biomarkers. Aβ PET+ versus Aβ CSF- findings are several-fold greater using regional Aβ PET analyses and in peri-threshold-standardized uptake value ratio participants. HIGHLIGHTS: Amyloid beta (Aβ) positron emission tomography (PET) has greater sensitivity for Aβ deposition than Aβ cerebrospinal fluid (CSF) in early Aβ development. A population-based sample of participants (n = 505) with PET and CSF tests was used. Cortical regions showing early Aβ on Aβ PET were also used in these analyses. Neuropathology was used to validate detection of Aβ by Aβ PET and Aβ CSF biomarkers.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.14317
Authors: Val J. Lowe, Carly T. Mester, Emily S. Lundt, Jeyeon Lee, Sujala Ghatamaneni, Alicia Algeciras‐Schimnich, Michelle R. Campbell, Jonathan Graff‐Radford, Aivi Nguyen, Hoon‐Ki Min, Matthew L. Senjem, Mary M. Machulda, Christopher G. Schwarz, Dennis W. Dickson, Melissa E. Murray, Karunya K. Kandimalla, Kejal Kantarci, Bradley Boeve, Prashanthi Vemuri, David T. Jones, David Knopman, Clifford R. Jack, Ronald C. Petersen, Michelle M. Mielke
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Funders: Mayo Clinic, Mayo Foundation for Medical Education and Research, GHR Foundation, Elsie and Marvin Dekelboum Family Foundation, Schuler-Stiftung, National Institutes of Health, Center for Neuroscience Research, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: G1269895679, G133088538, G159699970, G1797080948, G2212362641, G2333399577, G315872159, G344831414, G3782162780, G3930010334, G413369726, G4741916379, G5484535055, G5795572654, G5900136256, G60356126, G6064072631, G6875889451, Development, Validation, and Application of an Imaging based CVD Scale, G824560934, G8611190880, G9000005508, G9000009067, G9000014109, G9000019443, G9000020322, G9000030949, G9000037693, G9000043930, G9000093742, G9000096525, G9000163348, G9000167811, G9000172197, G9000201080, G9000235631, G9000259012, G9000290879, G9000323147, G9000338148, Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease, Tau PET/CT for Early Detection of Alzheimer’s Disease Pathology, Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSP, G924151532
OpenAlex ID: W4403337621